Please do not enter SM 6/6/05

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Daniel A. Gamache
David P. Bingaman
Michael A. Kapin

Serial No.: 10/660,152 (Conf. #4949)

Filed: September 11, 2003

For: PDE IV INHIBITORS TO TREAT ANGIOGENESIS

Group Art Unit: 1617

Examiner: Hui, S.

Atty. Dkt. No.: 1814 US

I hereby certify that this correspondence is being deposited with the United States Postal Service, with sufficient postage, as "Express Mail," Mailing Label EV 676 197 905 US in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:

17 May 2005
Date

Barbara McKenzie
Name

Barbara McKenzie

AMENDMENT and RESPONSE TO FINAL OFFICE ACTION DATED FEBRUARY 17, 2005

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Amendment is filed in response to the Final Official Action mailed February 17, 2005, for which the three-month date for response is May 17, 2005.

It is believed that no fee is due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason, the Assistant Commissioner is authorized to deduct said fees from Alcon Laboratories Deposit Account No. 01-0682.

Reconsideration of the application is respectfully requested.

There are no **Amendments to the Specification** in this paper.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

There are no **Amendments to the Drawings** in this paper.

Remarks/Arguments begin on page 3 of this paper.

05-18-05

IFW

AF/ 1617

Express Mail EV 676 197 905 US

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

OIPE MAY 17 2005 TC 1600 PATENT & TRADEMARK OFFICE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission	5

Application Number	10/660,152 (Conf #4949) ✓
Filing Date	11 September 2003
First Named Inventor	Daniel A. GAMACHE et al.
Art Unit	1617
Examiner Name	Hui, S
Attorney Docket Number	1814 US

ENCLOSURES *(Check all that apply)*

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☒ Amendment/Reply
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☐ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Reply to Missing Parts/ Incomplete Application
  - ☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____
  - ☐ Landscape Table on CD
- ☐ After Allowance Communication to TC
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC **(Appeal Notice, Brief, Reply Brief)**
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) (please Identify below):

  Return Card

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Alcon Research, Ltd.		
Signature	Teresa J. Schultz		
Printed name	Teresa J. Schultz		
Date		Reg. No.	40,526

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature	Barbara McKenzie		
Typed or printed name	Barbara McKenzie	Date	17 May 2005

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended) A method for treating posterior segment neovascularization which comprises, administering a pharmaceutically effective amount of a selective PDE-IV inhibitor, wherein the selective PDE-IV inhibitor is selected from the group consisting of 2-(4-ethoxycarbonylaminobenzyl)-6-(3,4-dimethoxyphenyl)-2,3,4,5-tetrahydro-pyridazin-3-one, 3-[3-(cyclopentyloxy)-4-methoxybenzyl]-6-(ethylamino)-8-isopropyl-3H-purine hydrochloride ~~(V-11294A)~~, 8-methoxyquinoline-5-[N-(2,5-dichloropyridin-3-yl)]carboxamide ~~(D-4418)~~, cipamfylline ~~(BRL-61063), ariflo (SB-207499)~~, and derivatives thereof.

Claim 2 (previously presented) The method of claim 1, wherein the posterior segment neovascularization is age-related macular degeneration.

Claim 3 (previously presented) The method of claim 2, wherein the age-related macular degeneration is exudative age-related macular degeneration.

Claim 4 (previously presented) The method of claim 1, wherein the posterior segment neovascularization is diabetic retinopathy.

Claim 5 (previously presented) The method of claim 4, wherein the diabetic retinopathy is proliferative diabetic retinopathy.

Claim 6 (previously presented) The method of claim 1, wherein the selective PDE-IV inhibitor is administered by oral administration, transdermally, subdermally, intraperitoneally, subcutaneously, transnasally, sublingually, rectally, by topical ocular administration, intravitreally, periocularly, transclerally, retrobulbar administration, sub-tenon injection, or via an intraocular device.